期刊文献+

脑肿瘤间质化疗BCNU缓释微球的载药量高效液相色谱测定

HPLC detection of BCNU loading of controlled-release microspheres in interstitial chemotherapy of cerebral tumors
下载PDF
导出
摘要 目的建立体外磷酸盐缓冲溶液(PBS)聚乳酸/羟基乙酸(PLGA)缓释卡氮芥(BCNU)微球药物浓度的高效液相色谱分析方法,并用此法研究缓释微球的体外释放动力学特征。方法采用依利特Hypersil ODS2 C18色谱柱(5μm,4.6mm×150mm),以甲醇:水(50:50)为流动相,流速1.0ml/min,紫外光检测波长237nm。结果BCNU在0.005—0.35μmol/ml范围内呈线性(r=0.9992),最低检测下限为0.005μmol/ml。采用低、中、高浓度(0.03、0.1、0.3μmol/m1)的方法回收率分别为103.33%、101.43%和102.04%,日间及日内相对标准偏差(RSD)分别〈4%和〈1%。体外药物释放动力学研究表明,PLGA缓释BCNU时间可达3w以上。结论本法准确可靠,操作简便,适用于缓释BCNU微球的体外药物释放动力学研究。 Objective To establish a method for the detection of carmustine (1,3-bis( 2-chloroethyl )-1- nitrosourea, BCNU) dose in phosphate-buffered solution (PBS) from BCNU-loaded (polylactic-co-glycolic acid, PIGA) microspheres and to study the releasing kinetics of BCNU-PIGA microspheres in vitro. Methods BCNU concentration was detected by an ultraviolet (UV) detector at 237 nm with a Hypersil ODS2 C18 column (5 μm, 4.6mm × 150 mm). The mixture of methanol and water (50 : 50) was used as the mobile phase. The flow rate was 1.0 ml/min. Results The calibration curve was linear within the range of 0. 005 ~ 0.35 μmol/ml and the measurable lowest limit was 0.005 μmol/ml. The average recovery rate of BCNU at the concentrations of 0.03, 0. 1 and 0. 3 μmol/ml was 103.33%, 101.43% and 102. 04% respectively. The relative standard deviation (RSD) of the within-day and between-days variation was less than 4% and 1% respectively. The results showed that the microspheres could release BCNU for over 3 weeks. Conclusion This high performance liquid chromatography method is simple, sensitive and accurate. It is suitable for released kinetics study of controlledrelease microspheres of BCNU loading in vitro.
出处 《中华神经外科疾病研究杂志》 CAS 2006年第6期522-525,共4页 Chinese Journal of Neurosurgical Disease Research
关键词 聚乳酸/羟基乙酸 卡氮芥 高效液相色谱法 药物释放动力学 Polylactic-co-glycolic acid 1,3-bis(2-chloroethyl)-1-nitrosourea High performance liquid chromatography Released kinetics
  • 相关文献

参考文献8

  • 1Hochberg FH,Pruitt AA,Beck DO,et al.The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma[J].J Neurosurg,1985,63(6):876-880. 被引量:1
  • 2Emerich DF,Tracy MA,Ward KL,et al.Biocompatibility of poly (D,L-lactide-co-glycolide) microspheres implanted into the brain[J].Cell Transplant,1999,8(1):47-58. 被引量:1
  • 3马晓东,Jerry R.Williams,Larry E.Dillehay,Jeffery A Williams.局部缓释IUdR治疗恶性星形细胞瘤实验研究(英文)[J].中华神经外科疾病研究杂志,2005,4(4):293-298. 被引量:3
  • 4de Jalon EG,Blanco-Prieto MJ,Ygartua P,et al.PLGA micro-particles:possible vehicles for topical drug delivery[J].Int J Pharm,2001,226(1-2):181-184. 被引量:1
  • 5Park TG.Degradation of poly(lactic-co-glycolic acid) microspheres:effect of copolymer composition[J].Biomaterials,1995,16(15):1123-1130. 被引量:1
  • 6Seong H,An TK,Khang G,et al.BCNU-loaded poly(D,L-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro[J].Int J Pharm,2003,251(1-2):1-12. 被引量:1
  • 7Tamada JA,Langer R.Erosion kinetics of hydrolytically degradable polymers[J].Proc Natl Acad Sci USA,1993,90(2):552-556. 被引量:1
  • 8Wang YM,Sato H,Adachi I,et al.Preparation and characterization of poly (lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent,Taxol[J].Chem Pharm Bull (Tokyo),1996,44(10):1935-1940. 被引量:1

二级参考文献8

  • 1Bashir R, Hochberg F, Oot R. Regrowth patterns of glioblastoma multiforme related to planning of intersatitial brachytherapy radiation fields [J]. Neurosurgery, 1988, 23(1): 27-30. 被引量:1
  • 2Wallner KE, Galicich J, Krol G, et al. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma [J]. Int J Radiat Oncol Biol Phys, 1989, 16(6): 1405-1409. 被引量:1
  • 3Leong KW, D'Amore PD, Marletta M, et al. Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity [J]. J Biomed Mat Res, 1986, 20(1): 51-64. 被引量:1
  • 4Brem H, Piantadosi S, Burger P, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group [J]. Lancet, 1995, 345(8956): 1008-1012. 被引量:1
  • 5Neshasteh-Riz A, Angerson WJ, Reeves JR, et al. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters [J]. British J Cancer, 1997, 75(4): 493-499. 被引量:1
  • 6Kassis AI, Adelstein SJ. Preclinical animal studies with radioiododeoxyuridine [J]. J Nucl Med, 1996, 37(4 Suppl): 10S-12S. 被引量:1
  • 7Mariani G, Collecchi P, Baldassarri S, et al. Tumor uptake and mitotic activity pattern of 5-[^125I]Iodo-2'-deoxyuridine after intravesical infusion in patients with bladder cancer [J]. J Nucl Med, 1996, 37(4 Suppl): 16S-19S. 被引量:1
  • 8Daghighian F, Humm JL, Macapinlac HA, et al. Pharmacokinekics and dosimetry of Iodine-125-IUdR in the treatment of colorectal cancer matastatic to liver [J]. J Nucl Med, 1996, 37 (4 Suppl): 29S-32S. 被引量:1

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部